Product Information

CAS No.	849675-66-7
Product Name	Encequidar

Biological Targets

ABCB1

Associated Conditions

breast cancer·neoplasm·angiosarcoma·breast neoplasm

* The information provided here is compiled from public sources and is for reference only.

Studies related to this compound and its mechanism of action

Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor.

Journal of medicinal chemistry • Vol. 64, Issue 7 • 2021

PMID: 33729781 DOI: 10.1021/acs.jmedchem.0c01826

Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: single- and multiple-dose randomized, placebo-controlled studies.

Clinical therapeutics • Vol. 34, Issue 2 • 2012

PMID: 22284902 DOI: 10.1016/j.clinthera.2012.01.003

Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel.

European journal of pharmacology • Vol. 627, Issue 1-3 • 2010

PMID: 19903471 DOI: 10.1016/j.ejphar.2009.11.008

Response of brain specific microenvironment to P-glycoprotein inhibitor: an important factor determining therapeutic effect of P-glycoprotein inhibitor on brain metastatic tumors.

International journal of oncology • Vol. 33, Issue 4 • 2008

PMID: 18813783

Encequidar

CAS No.	849675-66-7
MDL No.	MFCD25976625
MF	C₃₈H₃₆N₆O₇
MW	688.70
InChI Key	AHJUHHDDCJQACA-UHFFFAOYSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	849675-66-7
Product Name	Encequidar

Biological Targets

ABCB1

Associated Conditions

breast cancer·neoplasm·angiosarcoma·breast neoplasm

* The information provided here is compiled from public sources and is for reference only.

Encequidar

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Encequidar

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Documentation

Encequidar

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor.

Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: single- and multiple-dose randomized, placebo-controlled studies.

Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel.

Response of brain specific microenvironment to P-glycoprotein inhibitor: an important factor determining therapeutic effect of P-glycoprotein inhibitor on brain metastatic tumors.

Similar Products

HM-30181 mesylate monohydrate

Encequidar

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor.

Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: single- and multiple-dose randomized, placebo-controlled studies.

Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel.

Response of brain specific microenvironment to P-glycoprotein inhibitor: an important factor determining therapeutic effect of P-glycoprotein inhibitor on brain metastatic tumors.

Similar Products

HM-30181 mesylate monohydrate

Documentation